Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ID: DRG0XHDSX)
ADC Name
Belan-VA-I034 (8)
Synonyms
Belan-VA-I034 (8)
   Click to Show/Hide
Drug Status
Investigative
Drug-to-Antibody Ratio
8
Structure
Antibody Name
Belantamab
  Antibody Info 
Antigen Name
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
  Antigen Info 
Payload Name
I034
  Payload Info 
Payload Target
IKZF1/3
  Target Info 
Linker Name
MC-VA
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
90.41
%
Undisclosed Undisclosed
Tumor Growth Inhibition value (TGI) 
98.82
%
Undisclosed Undisclosed
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.01669
nM
CVCL_1600
Multiple myeloma
Half Maximal Degradation Concentration (DC50) 
0.06
nM
CVCL_1600
Multiple myeloma
Half Maximal Degradation Concentration (DC50) 
13.06
nM
CVCL_0140
Normal
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI)
90.41%
In Vivo Model NCI-H929 CDX 3 mpk (Day 25)
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI)
98.82%
In Vivo Model NCI-H929 CDX 6 mpk (Day25)
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.01669 nM
In Vitro Model Plasma cell myeloma NCI-H929 cells CVCL_1600
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Degradation Concentration (DC50)
0.06 nM
In Vitro Model Plasma cell myeloma NCI-H929 cells CVCL_1600
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Degradation Concentration (DC50)
13.06 nM
In Vitro Model Normal PBMC cells CVCL_0140
References
Ref 1 Rational engineering of degradation tail-driven CELMoD-antibody conjugates for precision malignancy therapy